A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol
DiscussionThis experimental medicine study provides a unique opportunity to gain detailed insights into the immunological mechanisms of belimumab-rituximab sequential therapy across multiple body compartments in the setting of AAV.Trial registrationClinicalTrials.gov NCT03967925. Registered on May 30, 2019.
Source: Trials - Category: Research Source Type: clinical trials
More News: Allergy & Immunology | Corticosteroid Therapy | Immunotherapy | Prednisolone | Research | Rituxan | Study | Vasculitis